Clinical trial of the anti-TIGIT/anti-PD-1 bispecific antibody AZD2936 in patients with advanced or metastatic non-small cell lung cancer.

THE OBJECTIVE OF THIS STUDY IS TO LEARN MORE ABOUT AZD2936, A NEW ANTIBODY THAT BLOCKS TWO PROTEINS (PD-1 AND TIGIT) AT THE SAME TIME. AZD2936 CAN BE USED IF UNRESECTABLE OR METASTATIC NON-SMALL CELL LUNG CANCER HAS BEEN DIAGNOSED. THE MAIN OBJECTIVE OF THIS STUDY IS TO GATHER INFORMATION ON THE CORRECT DOSE OF AZD2936 AND TO UNDERSTAND WHETHER THIS NEW DRUG CAN BE USEFUL FOR THE TREATMENT OF THE DIAGNOSED DISEASE. BOTH PD-1 AND TIGIT ARE CALLED "IMMUNE CHECKPOINTS". THEY EMIT SIGNALS THAT PREVENT THE BODY'S IMMUNE SYSTEM FROM ATTACKING TUMOR CELLS. THE BISPECIFIC FORMAT OF AZD2936 ALLOWS US TO BLOCK BOTH SIGNALS USING ONLY ONE DRUG. IN DOING SO, AZD2936 IS EXPECTED TO ENHANCE THE IMMUNE SYSTEM'S ABILITY TO ATTACK THE TUMOR.